Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

$2.02 -0.90 (-30.82%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+1.04%)

As of 10/2/2026 07:56 PM Eastern

Compare

Foghorn Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 10 Analyst Ratings

Sell
1

Hold
5

Buy
4

Based on 10 Wall Street analysts who have issued ratings for Foghorn Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 1 has given a sell rating, 5 have given a hold rating, and 4 have given a buy rating for FHTX.

Consensus Price Target

$6.67
230.03% Upside

According to the 10 analysts' twelve-month price targets for Foghorn Therapeutics, the average price target is $6.67. The highest price target for FHTX is $12.00, while the lowest price target for FHTX is $2.00. The average price target represents a forecasted upside of 230.03% from the current price of $2.02.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for FHTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Foghorn Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FHTX Analyst Ratings Over Time

Type	Current Forecast 10/3/25 to 10/3/26	1 Month Ago 9/3/25 to 9/3/26	3 Months Ago 7/5/25 to 7/5/26	1 Year Ago 10/3/24 to 10/3/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	4 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)
Hold	5 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$6.67	$11.43	$11.43	$11.50
Forecasted Upside	230.03% Upside	134.67% Upside	115.63% Upside	147.84% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Buy

FHTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FHTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Foghorn Therapeutics Stock vs. The Competition

Type	Foghorn Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	2.30	2.31	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	230.03% Upside	826.82% Upside	21.54% Upside
News Sentiment Rating	Neutral News See Recent FHTX News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/2/2026	Guggenheim 5 of 5 stars	Michael Schmidt 5 of 5 stars	Lower Target	Buy	$12.00 ➝ $5.00	+71.23%
10/2/2026	Wedbush 5 of 5 stars	Robert Driscoll 5 of 5 stars	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $2.00	-31.51%
10/2/2026	HC Wainwright 4 of 5 stars	Andres Y. Maldonado 5 of 5 stars	Lower Target	Buy	$13.00 ➝ $5.00	+71.23%
10/1/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
10/1/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeet Mukherjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
10/1/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Market Outperform ➝ Market Perform
10/1/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Prendergast Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$5.00	+78.89%
10/1/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
7/17/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
3/12/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Amin Makarem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
Get the Latest News and Ratings for FHTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/17/2025	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy	$10.00	+99.80%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:05 PM ET.

FHTX Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Foghorn Therapeutics is $6.67, with a high forecast of $12.00 and a low forecast of $2.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last twelve months. There is currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FHTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FHTX, but not buy additional shares or sell existing shares.

According to analysts, Foghorn Therapeutics's stock has a predicted upside of 230.03% based on their 12-month stock forecasts.

Over the previous 90 days, Foghorn Therapeutics's stock had 5 downgrades by analysts.

Foghorn Therapeutics has been rated by research analysts at BTIG Research, Citigroup, Citizens Jmp, Guggenheim, HC Wainwright, Stifel Nicolaus, TD Cowen, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Foghorn Therapeutics less than other "healthcare" companies. The consensus rating score for Foghorn Therapeutics is 2.30 while the average consensus rating score for "healthcare" companies is 2.31. Learn more on how FHTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Foghorn Therapeutics Recommendations

MarketBeat monitors more than a dozen sources for Foghorn Therapeutics analyst ratings, with the most recent rating issued on 10/2/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

FHTX Analyst Ratings Over Time

FHTX Analyst Recommendations By Month

FHTX Price Targets by Month

Foghorn Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

FHTX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Foghorn Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

FHTX Analyst Ratings Over Time

FHTX Analyst Recommendations By Month

FHTX Price Targets by Month

Foghorn Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

FHTX Forecast - Frequently Asked Questions

What is Foghorn Therapeutics' forecast for 2026?

Should I buy or sell Foghorn Therapeutics stock right now?

Does Foghorn Therapeutics's stock price have much upside?

Has Foghorn Therapeutics been downgraded by Wall Street analysts recently?

What analysts cover Foghorn Therapeutics?

Do Wall Street analysts like Foghorn Therapeutics more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Foghorn Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools